Furthermore, hepcidin could be used to define an algorithm along with other recent novel inflammatory biomarkers such as serum amyloid A protein (SAA) and mid-regional proadrenomedullin (MR-proADM) that have been recently evaluated for predicting mortality in COVID-19 patients [35,36]. This evidence concerns the gene SAA1 and COVID-19.